Vancomycin-TF (Vancomycin)

New highly effective glycopeptide antibiotic for systemic use with bactericidal activity against a wide range of gram-positive (+) bacteria, multiresistant nosocomial strains, including VanB-phenotype VRE. It can be administered once daily intramuscularly or intravenously as a bolus injection. The antibiotic has low toxicity and favorable tolerability. It is used in treatment of serious respiratory and urinary tract infections, skin and soft tissue infections, bone and joint infections, septicemia, endocarditis, peritonitis, infectious colitis.

An effective bactericidal antibiotic for the treatment of infections caused by gram-negative and gram-positive bacteria. It has a bactericidal effect on proliferating pathogenic microorganisms, preventing the enzymatic synthesis of the bacterial cell wall.

Antituberculous polypeptide antibiotic with low toxicity and and good tolerance. It is used for the treatment of drug-resistant forms of pulmonary tuberculosis.

The active ingredient of Claribaccin is clarithromycin. Clarithromycin is a semisynthetic macrolide antibiotic derived by substitution of CN3O hydroxyl group by (OH) group in the 6th position of the lactone ring of erythromycin, more precisely, clarithromycin is 6-Omethylerythromycin A. The mechanism of action of clarithromycin is based on binding to 50S ribosomal subunit of sensitive bacteria, which prevents the translocation of activated amino acids. Clarithromycin inhibits intracellular protein synthesis of microorganisms sensitive thereto and thereby exerts its antibacterial action.